

# ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: **Stock**

**Company** 2023/03/29 22:03:06

**Price**  
**158.00**  
USD

**Difference**  **-0.16%(-0.25)**



**Contact Details**

ABBVIE INC. Tel: +1-847-932-7900  
 -- Fax: +  
 1 North Waukegan Road Web: <http://www.abbvie.com>  
 60064-6400 North Chicago E-mail: -

## Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

## Financial figures

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	28,463,000,000		27,928,000,000		24,173,000,000	
<b>Common stock capital</b>		18,000,000		18,000,000		18,000,000
<b>Fixed assets</b>	110,342,000,000		118,601,000,000		126,392,000,000	
<b>Equity capital of a company</b>		17,287,000,000		15,436,000,000		13,097,000,000
<b>Cash and cash equivalents</b>	9,201,000,000		9,746,000,000		8,449,000,000	
<b>Accrued liabilities</b>		1,638,000,000		3,153,000,000		3,413,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		29,538,000,000		35,194,000,000		28,661,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		91,980,000,000		95,899,000,000		108,807,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		21,761,000,000		18,865,000,000		17,682,000,000
<b>Total assets</b>	138,805,000,000	138,805,000,000	146,529,000,000	146,529,000,000	150,565,000,000	150,565,000,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	50,000	50,000	47,000
<b>Equity ratio</b>	12.48%	10.55%	8.71%
<b>Debt-equity ratio</b>	701.41%	847.55%	1,047.77%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	12.11%	11.09%	-36.02%

# ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock**

## Income statement

	2022	2021	2020
Turnover	58,054,000,000	56,197,000,000	45,804,000,000
Net income	11,782,000,000	11,468,000,000	4,556,000,000
EBIT	14,508,008,600	14,287,192,200	5,328,355,400
Operating income before taxes	13,477,000,000	12,989,000,000	3,398,000,000
Cash Flow	24,943,000,000	22,777,000,000	17,588,000,000
Net interest income	-2,160,000,000	-2,410,000,000	-2,345,000,000
Research and development expenses	6,487,000,000	6,980,000,000	6,173,000,000
Income taxes	1,632,000,000	1,440,000,000	-1,224,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,077,250	1,042,792	904,190

## Board of Directors

## Members of Management Board

Robert Alpern	Member of Board of Directors
Brett Hart	Member of Board of Directors
Edward Rapp	Member of Board of Directors
Frederick Waddell	Member of Board of Directors
Glenn Tilton	Member of Board of Directors
Melody Meyer	Member of Board of Directors
Rebecca Roberts	Member of Board of Directors
Robert Michael	Member of Board of Directors
Roxanne Austin	Member of Board of Directors
Thomas Freyman	Member of Board of Directors
William Burnside	Member of Board of Directors
Richard Gonzalez	Chairman of Managing Board
Azita Saleki-Gerhardt	Member of Executive Committee
Chris Boone	Member of Executive Committee
Esteban Plata	Member of Executive Committee
Thomas Hudson	Member of Executive Committee
Brian Durkin	Member of Executive Committee
Carrie Strom	Member of Executive Committee
Henry Gosebruch	Member of Executive Committee
Jeffrey Stewart	Member of Executive Committee